Fogel & Partners acted as advisor to Isofol in connection with the entered license agreement with Solasia Pharma K.K

Fogel & Partners acted as advisor to Isofol in connection with the entered license agreement with Solasia Pharma K.K to develop and commercialize Isofol’s proprietary late-stage drug candidate arfolitixorin in Japan.

It was yesterday announced that Isofol Medical AB have entered into a license agreement with Solasia Pharma K.K, a specialized oncology company headquartered in Japan, to develop and commercialize Isofol’s proprietary late-stage drug candidate arfolitixorin as first-line treatment for metastatic colorectal cancer (mCRC) patients in Japan. Under the terms of the agreement, Isofol will receive a total amount of approximately USD 100 million (SEK 890 million) as upfront, development, regulatory and sales-based milestone payments. In addition, Isofol will receive tiered royalties on net sales in solid double digit figures.